1. Academic Validation
  2. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents

Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents

  • J Med Chem. 2001 Dec 20;44(26):4535-53. doi: 10.1021/jm010940+.
S Mahboobi 1 H Pongratz H Hufsky J Hockemeyer M Frieser A Lyssenko D H Paper J Bürgermeister F D Böhmer H H Fiebig A M Burger S Baasner T Beckers
Affiliations

Affiliation

  • 1 Faculty of Chemistry and Pharmacy, Institute of Pharmacy, University of Regensburg, D-93040 Regensburg, Germany. [email protected]@
Abstract

A new class of simple synthetic antimitotic compounds based on 2-aroylindoles was discovered. (5-Methoxy-1H-2-indolyl)-phenylmethanone (1) as well as analogous 3-fluorophenyl- (36) and 3-methoxyphenyl (3) derivatives displayed high cytotoxicity of IC(50) = 20 to 75 nM against the human HeLa/KB cervical, SK-OV-3 ovarian, and U373 astrocytoma carcinoma cell lines. The inhibition of proliferation correlated with the arrest in the G2/M phase of the cell cycle. In in vitro assays with tubulin isolated from bovine brain, in general antiproliferative activity correlated with inhibition of tubulin polymerization. Thus, the antimitotic activity of 2-aroylindoles is explained by interference with the mitotic spindle apparatus and destabilization of microtubules. In contrast to colchicine, vincristine, nocodazole, or taxol, 1 did not significantly affect the GTPase activity of beta-tubulin. Interestingly, selected compounds inhibited angiogenesis in the chorioallantoic membrane (CAM) assay. In xenograft experiments, 1 was highly active after oral administration at 200 mg/kg against the human amelanocytic melanoma MEXF 989 in athymic nude mice. We conclude, that 2-aroylindoles constitute an interesting new class of antitubulin agents with the potential to be clinically developed for Cancer treatment.

Figures
Products